Trial Profile
Protocol 2: Elucidation of Mechanisms Responsible for the Increase in EGP Following SGLT2 Inhibition: Decrease in Plasma Glucose Conc or Change in Islet Hormone (Glucagon/Insulin) Secretion
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms Protocol 2
- 02 Dec 2019 Status changed from active, no longer recruiting to completed.
- 15 Jan 2019 Planned End Date changed from 30 Dec 2018 to 31 Oct 2019.
- 15 Jan 2019 Status changed from recruiting to active, no longer recruiting.